HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025.

Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the National Cancer Centre Singapore (“NCCS”). He is a professor at Duke-NUS Medical School and serves as a senior clinician-scientist at the Genome Institute of Singapore.

Dr Dan Eldar, Chairman of HUTCHMED, said “On behalf of the Board, I would like to extend a warm welcome to Professor Tan. Professor Tan has a proven track record in early phase clinical trials of novel therapeutics, and we believe that his expertise in targeted therapies, biomarker development and clinical oncology will strongly support the strategic growth of the Company and drive continued innovation in cancer drug development.”

Professor Tan currently leads the Experimental Cancer Therapeutics Unit (ECRU) at the NCCS, one of Asia’s largest Phase I units, which runs approximately 30–40 trials at any time. He is also the Principal Investigator of the Cancer Therapeutics Research Laboratory at NCCS focused on developing representative patient-derived preclinical models to study drug response and resistance, complementing his leadership in multiple biomarker-driven early-phase and first-in-human clinical trials. He currently serves as the principal investigator of the National Medical Research Council (“NMRC”) Lung Cancer Large Collaborative Grant in Singapore (2025-2029 and previously 2019–2023) and chairs the Asian Thoracic Oncology Research Group, a regional platform for translational research and clinical trials.

Professor Tan’s research focuses on applying “omics” technologies to understand drug resistance and accelerate the development of novel therapies and biomarkers. His work has earned numerous accolades, including the International Association for the Study of Lung Cancer (IASLC) Daniel C. Idhe Lectureship Award for Medical Oncology, the American Society of Clinical Oncology (ASCO) Young Investigator Award, and the SingHealth Group Chief Executive Officer Outstanding Clinician-Researcher Award. He is a three-time recipient of the NMRC Clinician-Scientist Award.